# iBio to Participate in Upcoming Healthcare Investor Conferences
Canonical URL: https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-upcoming-healthcare-investor-conferences
Ticker: IBIO
Company: Ibio Inc
Source: Ibio Inc
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.ibioinc.com
## Summary

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator…...

## Article Body
June 02, 2026 4:01pm EDT

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. ( NASDAQ: IBIO ) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference.

Jefferies Global Healthcare Conference Presentation Date : Thursday, June 4, 2026 Time : 11:40 a.m. ET Location : Marriott Marquis, New York

A livestream of the event can be accessed link , and a replay of the presentation webcast will be available on the Investor Relations section of the iBio website for 90 days following the event.

Leerink Partners Therapeutics Forum: I&I and Metabolism Event Dates : July 14–15, 2026 Location : Boston Harbor Hotel, Boston

Dr. Brenner and Mr. Duran will participate in one-on-one investor meetings during the Leerink conference. Preliminary meeting schedules are expected to be available in mid-June.

To request a meeting with Dr. Brenner or Mr. Duran at either conference, please contact ir@ibioinc.com .

About iBio, Inc.

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn .

Contact:

iBio, Inc. Investor Relations ir@ibioinc.com

Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 or (646) 942-5604

Source: iBio, Inc. Released June 2, 2026
## Recent Company News
- 2026-07-01 11:00 EST — [iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study](https://biopharmsignal.com/news/IBIO/ibio-reports-single-dose-of-ibio-610-achieved-near-complete-active-activin-e-inh-15c14063) — Source: Ibio Inc
- 2026-06-25 13:46 EST — [iBio to Participate in Upcoming Healthcare Investor Conferences](https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-upcoming-healthcare-investor-conferences) — Source: Ibio Inc
- 2026-06-25 13:46 EST — [iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity](https://biopharmsignal.com/news/IBIO/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity) — Source: Ibio Inc
- 2026-06-25 13:46 EST — [iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/IBIO/ibio-reports-q3-fiscal-year-2026-financial-results-and-provides-corporate-update) — Source: Ibio Inc
- 2026-06-25 13:46 EST — [iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors](https://biopharmsignal.com/news/IBIO/ibio-appoints-distinguished-biotech-leader-elizabeth-stoner-to-its-board-of-directors) — Source: Ibio Inc
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)